Zhongzhi Pharmaceutical Holdings Ltd 2022 AR2
The report outlines Zhongzhi Pharmaceutical Holdings Limited's financial and sustainability performance for the fiscal year 2022. Key highlights include a 4.5% increase in revenue to RMB 1,825.9 million and a 104.1% surge in profit attributable to owners to RMB 106.4 million. In sustainability, the company successfully put its Yunfu Factory into operation and continued to advance its cell-broken herbs (CaoJingHua) segment. Additionally, the Group achieved zero work-related fatalities and reduced its total non-hazardous waste by approximately 64% compared to the previous year.
Company: Zhongzhi Pharmaceutical Holdings Ltd
Sector: Health Care
Country: China
Year: 2022
Type: AR2
Pages: 189
Zhongzhi Pharmaceutical Holdings Ltd
Annual Report
The report outlines Zhongzhi Pharmaceutical Holdings Limited's financial and sustainability performance for the fiscal year 2022. Key highlights include a 4.5% increase in revenue to RMB 1,825.9 million and a 104.1% surge in profit attributable to owners to RMB 106.4 million. In sustainability, the company successfully put its Yunfu Factory into operation and continued to advance its cell-broken herbs (CaoJingHua) segment. Additionally, the Group achieved zero work-related fatalities and reduced its total non-hazardous waste by approximately 64% compared to the previous year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Mar 22, 2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees